Author(s): Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA
Abstract Share this page
Abstract OBJECTIVE: To determine the efficacy of minocycline in the treatment of rheumatoid arthritis (RA). METHODS: Minocycline (maximal oral daily dose 200 mg) or placebo was administered in a 26-week, randomized, double-blind study to 80 patients with active RA, who were treated or had previously been treated with at least one disease-modifying antirheumatic drug. RESULTS: There were 15 premature discontinuations: 6 (5 taking minocycline) because of adverse effects, 8 (all taking placebo) because of lack of efficacy, and 1 (taking placebo) because of intercurrent illness. There was a statistically significant improvement in the minocycline group over the placebo group. There was a pronounced improvement in laboratory parameters of disease activity; however, improvement in clinical parameters was less impressive. The observed adverse effects attributable to minocycline were mainly gastrointestinal symptoms and dizziness. CONCLUSION: The results of the present study suggest that minocycline is beneficial and relatively safe in RA patients.
This article was published in Arthritis Rheum
and referenced in Journal of Nanomedicine & Biotherapeutic Discovery